155 related articles for article (PubMed ID: 30288144)
1. Prostate Biopsy Characteristics: A Comparison Between the Pre- and Post-2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Guidelines.
Shah N; Ioffe V; Huebner T; Hristova I
Rev Urol; 2018; 20(2):77-83. PubMed ID: 30288144
[TBL] [Abstract][Full Text] [Related]
2. Prostate Biopsy Features: A Comparison Between the Pre- and Post-2012 United States Preventive Services Task Force Prostate Cancer Screening Guidelines With Emphasis on African American and Septuagenarian Men.
Shah N; Ioffe V; Cherone S
Rev Urol; 2019; 21(1):1-7. PubMed ID: 31239823
[TBL] [Abstract][Full Text] [Related]
3. A Trend Toward Aggressive Prostate Cancer.
Shah N; Ioffe V
Rev Urol; 2020; 22(3):102-109. PubMed ID: 33239969
[TBL] [Abstract][Full Text] [Related]
4. Increasing aggressive prostate cancer.
Shah N; Ioffe V; Chang JC
Can J Urol; 2022 Dec; 29(6):11384-11390. PubMed ID: 36495581
[TBL] [Abstract][Full Text] [Related]
5. Prostate biopsy characteristics: A comparison between pre- and post- United States Preventive Service Task Force Prostate Cancer Screening Guidelines of 2012.
Shah N; Huebner T; Ioffe V; Hum R
Rev Urol; 2017; 19(1):25-31. PubMed ID: 28522927
[TBL] [Abstract][Full Text] [Related]
6. Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening.
Zakaria AS; Dragomir A; Brimo F; Kassouf W; Tanguay S; Aprikian A
BMC Urol; 2018 Aug; 18(1):69. PubMed ID: 30126402
[TBL] [Abstract][Full Text] [Related]
7. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
[TBL] [Abstract][Full Text] [Related]
8. US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses.
Gejerman G; Ciccone P; Goldstein M; Lanteri V; Schlecker B; Sanzone J; Esposito M; Rome S; Ciccone M; Margolis E; Simon R; Guo Y; Pentakota SR; Sadeghi-Nejad H
Investig Clin Urol; 2017 Nov; 58(6):423-428. PubMed ID: 29124241
[TBL] [Abstract][Full Text] [Related]
9. Metastatic prostate cancer incidence in Australia after amendment to prostate-specific antigen screening guidelines.
Smith S; Wolanski P
ANZ J Surg; 2018; 88(7-8):E589-E593. PubMed ID: 29194902
[TBL] [Abstract][Full Text] [Related]
10. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
11. Impact of United States Preventive Services Task Force recommendations on prostate biopsy characteristics and disease presentation at a tertiary-care medical center.
Blair BM; Robyak H; Clark JY; Kaag MG; Lehman EB; Raman JD
Prostate Int; 2018 Sep; 6(3):110-114. PubMed ID: 30140661
[TBL] [Abstract][Full Text] [Related]
12. Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening.
Banerji JS; Wolff EM; Massman JD; Odem-Davis K; Porter CR; Corman JM
J Urol; 2016 Jan; 195(1):66-73. PubMed ID: 26254722
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
[TBL] [Abstract][Full Text] [Related]
14. Histologic Changes in Prostate Cancer Detected Subsequent to the 2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Recommendation.
Olsson CA; Lavery HJ; Yadav KK; Anderson AE; Kapoor D
Rev Urol; 2018; 20(3):125-130. PubMed ID: 30473638
[TBL] [Abstract][Full Text] [Related]
15. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
[TBL] [Abstract][Full Text] [Related]
16. Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice.
Gaylis FD; Choi JE; Hamilton Z; Dato P; Cohen E; Calabrese R; Prime H; Rosenbaum A; Kader AK
Urol Oncol; 2017 Nov; 35(11):663.e1-663.e7. PubMed ID: 28736250
[TBL] [Abstract][Full Text] [Related]
17. Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates.
Bhindi B; Mamdani M; Kulkarni GS; Finelli A; Hamilton RJ; Trachtenberg J; Zlotta AR; Evans A; van der Kwast TH; Toi A; Fleshner NE
J Urol; 2015 May; 193(5):1519-24. PubMed ID: 25481037
[TBL] [Abstract][Full Text] [Related]
18. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
[TBL] [Abstract][Full Text] [Related]
19. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
Dell'Atti L
J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]